Boehringer Ingelheim International Gmbh

Sprout Pharmaceuticals, Inc.

Boehringer Ingelheim Pharma Kg

Other

Boehringer Ingelheim Pharma Gmbh & Co Kg

Angelo Ceci

Norbert Hauel

Henri Doods

Ingo Konetzki

Annette Schuler-Metz

Rainer Walter

Iris Kauffmann-Hefner

Dieter Wiedenmayer

Marcus Schindler

Riccardo Giovannini

Roland Pfau

Cornelia Dorner-Ciossek

Thomas Weiser

Karin Winter

Henning Priepke

Juergen Mack

Heiner Ebel

Stefan Matthias Blech

Ramiro Castro

Birgit Jung

Georg Dahmann

Stefan Peters

Raimund Kuelzer

Enzo Cereda

Klaus Klinder

Lothar Kussmaul

Disclosed are 4-pyrazin-2-ylmethyl-morpholines of formula A and pharmaceutically acceptable salts thereof, wherein Rand Rare defined herein. Also disclosed are processes for their preparation, pharmaceutical compositions containing the compounds, and their use in therapy, particularly in the treatment or prevention of conditions having an association with NR2B negative allosteric modulating properties.

4-pyrazin-2-ylmethyl-morpholine derivatives and the use thereof as medicament

Disclosed are 4-pyridinylmethyl-morpholines of formula A and pharmaceutically acceptable salts thereof, wherein Rand Rare defined herein. Also disclosed are processes for their preparation, pharmaceutical compositions containing the compounds, and their use in therapy, particularly in the treatment or prevention of conditions having an association with NR2B negative allosteric modulating properties.

4-pyridinylmethyl-morpholine derivatives and the use thereof as medicament

Disclosed are 4-pyrimidin-5-ylmethyl-morpholines of formula A and pharmaceutically acceptable salts thereof, wherein Rand Rare defined herein. Also disclosed are processes for their preparation, pharmaceutical compositions containing the compounds, and their use in therapy, particularly in the treatment or prevention of conditions having an association with NR2B negative allosteric modulating properties.

4-pyrimidin-5-ylmethyl-morpholine derivatives and the use thereof as medicament

The invention relates to compositions for the treatment of obesity and related diseases comprising a) an active substance being not flibanserin, selected from the group consisting of active substances for the treatment of obesity and obesity related diseases and b) flibanserin, optionally in the form of pharmacologically acceptable acid addition salts thereof.

Use of Flibanserin in the treatment of obesity

The present invention relates to imidazopyridines of formula A processes for their preparation, pharmaceutical compositions containing them and their use in therapy, particularly in the treatment or prevention of conditions having an association with NR2B negative allosteric modulating properties.

Imidazopyridine derivatives and the use thereof as medicament

Use of flibanserin in the treatment of obesity

The invention relates to the use of Flibanserin for the treatment or prevention of urinary incontinence and related diseases. In a further embodiment, the instant invention is directed to pharmaceutical combinations comprising flibanserin as one active ingredient in combination with at least one additional active ingredient for the treatment or prevention of urinary incontinence and related diseases.

Flibanserin for the treatment of urinary incontinence and related diseases

Disubstituted tetrahydrofuranyl compounds of general formula I of which the following are exemplary: 

Disubstituted tetrahydrofuranyl compounds and their use as B1-receptor antagonists

The present invention relates to compounds of general formula I wherein n, R, R, R, R, R, R, Rand Rare defined as stated hereinafter, the enantiomers, the diastereomers, the mixtures thereof and the salts thereof, particularly the physiologically acceptable salts thereof with organic or inorganic acids or bases, which have valuable properties, the preparation thereof, the pharmaceutical compositions containing the pharmacologically effective compounds, the preparation thereof and the use thereof.

Bradykinin B1-antagonists

Disclosed are compounds of the formula I wherein A, Y, R, R, R, Rand Rare defined, suitable for treating diseases and symptoms of diseases caused at least to some extent by stimulation of bradykinin-B1 receptors, the preparation thereof and the use thereof.

B1-antagonists

The invention relates to a method for the treatment of obesity and related diseases comprising the administration of a therapeutically effective amount of Flibanserin.

Novel compounds which are useful for treating acute pain, visceral pain, neuropathic pain, inflammatory/pain receptor-mediated pain, tumor pain and headache diseases. The following is exemplary: 

Bradykinin B1-receptor antagonists

Novel compounds of which the following is exemplary: 

Growing community of inventors

Mittelbiberach, Germany

Angelo Ceci